AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
RPRX vs MSFT Fundamental Comparison
| Metric | RPRX | MSFT |
|---|---|---|
| Revenue | $2.4B | $158.9B |
| Net Income | $770.9M | $66.2B |
| Net Margin | 32.4% | 41.7% |
| ROE | 7.9% | 16.9% |
| ROA | 3.9% | 10.0% |
| Current Ratio | 2.40x | 1.39x |
| Debt/Equity | 0.92x | 0.10x |
| EPS | $1.78 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RPRX vs MSFT: Frequently Asked Questions
Is RPRX or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. RPRX is rated HOLD (75% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does RPRX compare to MSFT fundamentally?
Royalty Pharma plc has ROE of 7.9% vs MICROSOFT CORP's 16.9%. Net margins are 32.4% vs 41.7% respectively.
Which stock pays higher dividends, RPRX or MSFT?
RPRX has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RPRX or MSFT for long term?
For long-term investing, consider that RPRX has HOLD rating with 75% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RPRX vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RPRX vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.